Latest Content

Dr. Jason Konner discusses psilocybin, clinician burnout, CIPN prevention, and safety protocols for oncology nurses and care teams in cancer care.

Non-CME PER® Podcast

FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.

ANA President Jennifer Mensik Kennedy outlines systemic nurse fatigue mitigation policies, emphasizing patient safety and acuity across oncology care.

From ICN 2026, Heather Jackson and Ashley Johnson detail APP breast care access models, global cancer pain barriers, and burnout mitigation tactics.

FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.

Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.

Yesne Alici, MD, of Memorial Sloan Kettering Cancer Center discusses key delirium screening, patient capacity, and bioethics in oncology nursing care.

A nurse-led support program significantly reduces death anxiety in women with breast cancer on hormonal therapy, study finds.

Erik Bengtsen, MD, of Memorial Sloan Kettering Cancer Center, discusses psilocybin research, demoralization, and psychopharmacology in oncology care.

Ramy Sedhom, MD, of Penn Medicine Princeton Health discusses blending palliative care with psycho-oncology to treat patient distress in oncology care.

FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.

At WCLC 2026, Kaitlyn Gregory details key oncology nursing insights into exercise, caregiver stress, screening models, and APP-led supportive care.